Parataxis Korea
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Parataxis Korea operates two distinct businesses: a digital-asset division that holds Bitcoin as a strategic treasury asset and runs Bitcoin-mining infrastructure, and a biopharmaceutical division that researches and develops novel drugs for diseases such as idiopathic pulmonary fibrosis and lung cancer.
Its drug candidates are aimed at patients with high unmet medical needs, with the business model centered on licensing pipeline assets to partners in the near term and direct commercialization over the longer term. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company runs these two divisions in parallel, with the digital-asset arm being a recent addition funded through a capital raise.
Summary is AI-generated and may contain errors · figures from DART filings
The digital-asset division was established using funds raised from a capital injection by Parataxis Holdings, making that entity a named funding source disclosed in the company's official filing.
Parataxis Korea in five facts
What does Parataxis Korea do?
Parataxis Korea operates two distinct businesses: a digital-asset division that holds Bitcoin as a strategic treasury asset and runs Bitcoin-mining infrastructure, and a biopharmaceutical division that researches and develops novel drugs for diseases such as idiopathic pulmonary fibrosis and lung cancer.
Where is Parataxis Korea listed and in which sector?
Parataxis Korea (Korean name: 파라택시스코리아) trades under KRX code 288330 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Parataxis Korea?
Its market capitalisation was US$33.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Parataxis Korea's latest annual revenue and operating profit?
For fiscal year 2025, Parataxis Korea reported revenue of US$6.8K, an operating loss of US$11.4M and a net loss of US$24.3M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 313.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Shareholder register closure / record date setOct 6
- [Amended] Resolution to convene a general shareholders' meetingOct 6
- Other material management matterOct 6
- [Amended] Material event report (merger)M&A · Oct 6
- [Amended] Material event report (merger)
Parataxis Korea Co., Ltd. amended its April 7, 2026 merger report to update the merger schedule, wording, and a clerical error in the reference-price calculation, in connection with its planned absorption by affiliate Parataxis Ethereum Co., Ltd. at a merger ratio of 1 : 0.2806763; the Korea Exchange's Corporate Review Committee resolved on July 1, 2026 to delist Parataxis Korea Co., Ltd.'s shares, a development that may require the merger ratio and terms to be revised.
M&A · Jul 21 - [Amended] Material event report (merger)M&A · Apr 9
- Material event report (merger)M&A · Apr 8
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Parataxis Korea reported consolidated results for FY2025: revenue of US$5.99K (+313.2% year on year), an operating loss of US$10.1M and a net loss of US$16.3M.
Earnings · Mar 16